383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping.

MLA

Yang, J. .. H., et al. “383MO Tepotinib in Asian Patients (Pts) with Advanced NSCLC with MET Exon 14 (METex14) Skipping.” Annals of Oncology, vol. 31, Nov. 2020, pp. S1390–91. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.10.377.

APA

Yang, J. .-H., Le, X., Cho, B. C., Han, J.-Y., Morise, M., Chen, Y.-M., Kang, J.-H., Kato, T., Takeoka, H., Chikamori, K., Sakai, H., Park, K., Wu, Y.-L., Schumacher, K., Bruns, R., Straub, J., & Paik, P. (2020). 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping. Annals of Oncology, 31, S1390–S1391. https://doi.org/10.1016/j.annonc.2020.10.377

Chicago

Yang, J.C-H., X. Le, B.C. Cho, J-Y. Han, M. Morise, Y-M. Chen, J-H. Kang, et al. 2020. “383MO Tepotinib in Asian Patients (Pts) with Advanced NSCLC with MET Exon 14 (METex14) Skipping.” Annals of Oncology 31 (November): S1390–91. doi:10.1016/j.annonc.2020.10.377.